ANZCTR registration et al., 2023-11-09: Registry entry for a 19-item ReDO protocol case series in Queensland with a target of 50 patients. Fenbendazole appears as item 13 at 100 mg twice daily, combined with mebendazole in the same line, alongside 18 other drugs and supplements.
Mebendazole / Fenbendazole 100 mg x2
ANZCTR registration et al., 2023-11-09: Registry entry for a 19-item ReDO protocol case series in Queensland with a target of 50 patients. Fenbendazole appears as item 13 at 100 mg twice daily, combined with mebendazole in the same line, alongside 18 other drugs and supplements. Trial registry record field, not prose: the excerpt is the item line transcribed from the intervention table, hence MEDIUM confidence. Interventional, single-arm case series, patients are their own control; target 50, accrual 30 at last update (13 December 2025); Australia (Willow Vale, Queensland); fenbendazole/mebendazole 100 mg x 2 per day as one of 19 items given for 90 days after a 2-month introduction. Funder: patients at the Willow Vale Clinic; sponsor Dr Taufiq Binjemain. Declared conflicts: none stated. Comparator: none, patients serve as their own control. Primary outcome is circulating tumour cell count, not survival or tumour response; no results posted. The registry line does not separate the mebendazole and fenbendazole doses, so the fenbendazole dose cannot be stated from this record. Registry entry; no results posted. Study type: uncontrolled series.
